title: Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
authors: M
authors: M
authors: Kim
authors: M
authors: M
authors: Li
authors: L R A
authors: LR
authors: Intong
authors: K
authors: K
authors: Tran
authors: W
authors: W
authors: Melbourne
authors: D
authors: D
authors: Marucci
authors: J
authors: J
authors: Bucci
authors: P
authors: P
authors: de Souza
authors: G
authors: G
authors: Mallesara
authors: D F
authors: DF
authors: Murrell
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D016108:Epidermolysis Bullosa Dystrophica / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab